Investigation of a selective androgen receptor modulator (SARM) RAD 140 [Radius Health] for the treatment of age-related muscle-wasting and other musculoskeletal conditions such as osteoporosis.

Trial Profile

Investigation of a selective androgen receptor modulator (SARM) RAD 140 [Radius Health] for the treatment of age-related muscle-wasting and other musculoskeletal conditions such as osteoporosis.

Planning
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 17 Jun 2008

At a glance

  • Drugs RAD 140 (Primary)
  • Indications Muscular atrophy; Osteoporosis
  • Focus Therapeutic Use
  • Sponsors Radius Health Inc.
  • Most Recent Events

    • 17 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top